Search

Displaying results 1731 - 1740 of 4591 in total
  1. Drug

    Docetaxel

    go.drugbank.com/drugs/DB01248
    ApprovedInvestigational

    Docetaxel binds to microtubules but does not interact with dimeric tubulin. … [L46466] Docetaxel was approved by the FDA in 1996 and is available in solution for injection for intravenous or parenteral administration.[A259676]

  2. Drug

    Marnetegragene autotemcel

    go.drugbank.com/drugs/DB17595
    Approved

    [L56116, A275467] Allogeneic hematopoietic stem cell transplant is a curative option but is limited by issues such as donor availability, a high incidence of graft-versus-host disease, and graft failure

  3. Drug

    Bebtelovimab

    go.drugbank.com/drugs/DB16755
    ApprovedWithdrawn

    On November 30, 2022, the EUA for bebtelovimab was officially withdrawn due to a lack of efficacy against Omicron subvariants, therefore bebtelovimab is no longer authorized for emergency use in the US … [L40328] Bebtelovimab was issued an emergency use authorization (EUA) by the FDA on February 11, 2022, for the treatment of mild-to-moderate COVID-19 in select patients.

  4. Drug

    Roxadustat

    go.drugbank.com/drugs/DB04847
    ApprovedInvestigational

    [A245393] Roxadustat was first approved by the European Commission in August 2021.[L40323] … It works by reducing the breakdown of the hypoxia-inducible factor (HIF), which is a transcription factor that stimulates red blood cell production in response to low oxygen levels.

  5. Drug

    Fluticasone

    go.drugbank.com/drugs/DB13867
    ApprovedInvestigationalWithdrawn

    Fluticasone is a synthetic glucocorticoid available as 2 esters, DB08906 and DB00588 [FDA Label]. These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory indications [FDA Label]. DB00588 was ...

  6. Drug

    CM4620

    go.drugbank.com/drugs/DB16466
    Investigational

    CM4620 (Zegocractin), is under investigation in multiple clinical trials, including NCT04195347 (pancreatitis due to asparaginase), NCT03709342 (PK/PD study in acute pancreatitis), NCT03401190 and NCT04681066

  7. Drug

    Bitolterol

    go.drugbank.com/drugs/DB00901
    ApprovedWithdrawn

    Bitolterol was withdrawn from the market by Elan Pharmaceuticals in 2001.

  8. Drug

    Paroxetine

    go.drugbank.com/drugs/DB00715
    ApprovedInvestigational

    [T653] It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham.

  9. Drug

    NV-07a

    go.drugbank.com/drugs/DB05845
    Experimental

    NV-07a is topical skin repair compound protecting skin from sun-induced immunosuppression and UV-induced damage.

  10. Drug

    Phenelzine

    go.drugbank.com/drugs/DB00780
    ApprovedInvestigational

    [A15753] It was developed by Parke Davis and originally FDA approved on June 9th, 1961. It is currently approved under prescription by the name of Nardil.